InflaRx N.V.: Business Overview, Financials & Competitive Analysis
InflaRx N.V. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage biotech with differentiated C5a-targeting approach facing near-term catalysts that could significantly de-risk pipeline but carrying inherent clinical development risk. InflaRx has a strong technology platform and multiple clinical programs advancing through key milestones, but remains clinical-stage with no approved commercial products beyond EUA for COVID-19. Financial runway appears adequate.
What is InflaRx N.V.'s industry? InflaRx N.V. (inflarx.de) operates in Biopharmaceutical - Immunology/Inflammatory Diseases. AskCyborg classifies InflaRx N.V. under Biopharmaceutical - Immunology/Inflammatory Diseases in its company registry.
InflaRx is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology, where C5a is an inflammatory mediator involved in the progression of autoimmune and other inflammatory...
Cyborg Score thesis
Early-stage biotech with differentiated C5a-targeting approach facing near-term catalysts that could significantly de-risk...
Read the full analyst-debate transcript →Get the Latest InflaRx N.V. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeInflaRx N.V. Overview
Pro stress-test →InflaRx is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology, where C5a is an inflammatory mediator involved in the progression of autoimmune and other inflammatory diseases. The company applies its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR.
Strategic Profile
Pro stress-test →The company's lead product candidate is vilobelimab, a first-in-class anti-C5a monoclonal antibody, which completed Phase III clinical trials for hidradenitis suppurativa and is in Phase II development for anti-neutrophil cytoplasm antibody associated vasculitis and other indications. Multiple near-term catalysts are anticipated including interim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum with recommendation expected end of May to early June, and topline data for INF904 Phase 2a trial expected in summer 2025.
Competitive Landscape
Pro stress-test →InflaRx has a co-development agreement with Beijing Defengrei Biotechnology and clinical trial collaboration and supply agreement with Merck & Co. The company competes within the complement inhibitor space targeting rare inflammatory and autoimmune diseases with limited competition in C5a-specific targeting, though broader anti-inflammatory and immunology programs exist from larger pharma companies.
Industry Context
InflaRx N.V. operates in Biopharmaceutical - Immunology/Inflammatory Diseases.
Key facts
Founded: 2007 · Headquarters: Jena, Germany · Employees: 74 · Market cap: $68.43M USD